David A. Fraser

Amsterdam, NH, Netherlands

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 13 publications

A medium-chain fatty acid analogue prevents endotoxin liver injury in a murine model.

A medium-chain fatty acid analogue prevents endotoxin liver injury in a murine model.

Journal: Scientific reports

Published: November 21, 2024

A phase IIb randomised-controlled trial of the FFAR1/FFAR4 agonist icosabutate in MASH.

A phase IIb randomised-controlled trial of the FFAR1/FFAR4 agonist icosabutate in MASH.

Journal: Journal of hepatology

Published: July 23, 2024

A medium-chain fatty acid analogue prevents hepatosteatosis and decreases inflammatory lipid metabolites in a murine model of parenteral nutrition-induced hepatosteatosis.

A medium-chain fatty acid analogue prevents hepatosteatosis and decreases inflammatory lipid metabolites in a murine model of parenteral nutrition-induced hepatosteatosis.

Journal: PloS one

Published: August 15, 2023

A Medium-Chain Fatty Acid Analogue Prevents Intestinal Failure-Associated Liver Disease in Preterm Yorkshire Piglets.

A Medium-Chain Fatty Acid Analogue Prevents Intestinal Failure-Associated Liver Disease in Preterm Yorkshire Piglets.

Journal: Gastroenterology

Published: February 16, 2023

Icosabutate: targeting metabolic and inflammatory pathways for the treatment of NASH.

Icosabutate: targeting metabolic and inflammatory pathways for the treatment of NASH.

Journal: Expert opinion on investigational drugs

Published: December 17, 2022

Structurally-engineered fatty acid 1024 (SEFA-1024) improves diet-induced obesity, insulin resistance, and fatty liver disease.

Structurally-engineered fatty acid 1024 (SEFA-1024) improves diet-induced obesity, insulin resistance, and fatty liver disease.

Journal: Lipids

Published: December 19, 2021

A structurally engineered fatty acid, icosabutate, suppresses liver inflammation and fibrosis in NASH.

A structurally engineered fatty acid, icosabutate, suppresses liver inflammation and fibrosis in NASH.

Journal: Journal of hepatology

Published: January 07, 2021

Dual targeting of hepatic fibrosis and atherogenesis by icosabutate, an engineered eicosapentaenoic acid derivative.

Dual targeting of hepatic fibrosis and atherogenesis by icosabutate, an engineered eicosapentaenoic acid derivative.

Journal: Liver international : official journal of the International Association for the Study of the Liver

Published: April 27, 2020

Icosabutate Exerts Beneficial Effects Upon Insulin Sensitivity, Hepatic Inflammation, Lipotoxicity, and Fibrosis in Mice.

Icosabutate Exerts Beneficial Effects Upon Insulin Sensitivity, Hepatic Inflammation, Lipotoxicity, and Fibrosis in Mice.

Journal: Hepatology communications

Published: August 22, 2019

Icosabutate, a Structurally Engineered Fatty Acid, Improves the Cardiovascular Risk Profile in Statin-Treated Patients with Residual Hypertriglyceridemia.

Icosabutate, a Structurally Engineered Fatty Acid, Improves the Cardiovascular Risk Profile in Statin-Treated Patients with Residual Hypertriglyceridemia.

Journal: Cardiology

Published: January 26, 2016

Icosabutate for the treatment of very high triglycerides: A placebo-controlled, randomized, double-blind, 12-week clinical trial.

Icosabutate for the treatment of very high triglycerides: A placebo-controlled, randomized, double-blind, 12-week clinical trial.

Journal: Journal of clinical lipidology

Published: July 03, 2015

Triglycerides-diabetes association in healthy middle-aged men: modified by physical fitness? A long term follow-up of 1962 Norwegian men in the Oslo Ischemia Study.

Triglycerides-diabetes association in healthy middle-aged men: modified by physical fitness? A long term follow-up of 1962 Norwegian men in the Oslo Ischemia Study.

Journal: Diabetes research and clinical practice

Published: October 05, 2012

Showing 1-12 of 13

Last Updated: 09/26/2026